BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 9398908)

  • 1. Treatment of Helicobacter pylori infection: a review of the world literature.
    van der Hulst RW; Keller JJ; Rauws EA; Tytgat GN
    Helicobacter; 1996 Mar; 1(1):6-19. PubMed ID: 9398908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
    Mégraud F; Malfertheiner P
    Helicobacter; 1996 Jun; 1(2):118-21. PubMed ID: 9398889
    [No Abstract]   [Full Text] [Related]  

  • 3. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial.
    Xie Y; Pan X; Li Y; Wang H; Du Y; Xu J; Wang J; Zeng Z; Chen Y; Zhang G; Wu K; Liu D; Lv N
    J Antimicrob Chemother; 2018 Jun; 73(6):1681-1687. PubMed ID: 29596646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of
    Varga M; Drácz L; Kolbenheyer E; Varga F; Patai ÁV; Solymosi N; Patai Á
    Orv Hetil; 2019 Aug; 160(34):1340-1345. PubMed ID: 31423829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pylera for the eradication of Helicobacter pylori infection.
    Saleem A; Qasim A; O'Connor HJ; O'Morain CA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.
    Yurenev GL; Partzvania-Vinogradova EV; Andreev DN; Dicheva DT; Maiev IV
    Ter Arkh; 2018 Aug; 90(8):33-39. PubMed ID: 30701937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
    Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
    Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
    Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.
    Lind T; Veldhuyzen van Zanten S; Unge P; Spiller R; Bayerdörffer E; O'Morain C; Bardhan KD; Bradette M; Chiba N; Wrangstadh M; Cederberg C; Idström JP
    Helicobacter; 1996 Sep; 1(3):138-44. PubMed ID: 9398894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it time for quadruple therapy to be first line?
    Laine L
    Can J Gastroenterol; 2003 Jun; 17 Suppl B():33B-35B. PubMed ID: 12905979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
    Calvet X; Montserrat A; Güell M; Vergara M; Gené E
    Eur J Gastroenterol Hepatol; 2004 Oct; 16(10):987-90. PubMed ID: 15371921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
    Fallone CA; Chiba N; van Zanten SV; Fischbach L; Gisbert JP; Hunt RH; Jones NL; Render C; Leontiadis GI; Moayyedi P; Marshall JK
    Gastroenterology; 2016 Jul; 151(1):51-69.e14. PubMed ID: 27102658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy.
    Tarhini M; Fayyad-Kazan M; Fayyad-Kazan H; Mokbel M; Nasreddine M; Badran B; Kchour G
    Microb Pathog; 2018 Apr; 117():23-26. PubMed ID: 29428426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.